Skip to main content

Effects of Danhong Injection on 90-Day Functional Outcome in Acute Ischemic Stroke: An Adaptive, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Trial

In brief

Danhong injection raised 90-day good outcomes from 59% to 65% after stroke

In a randomized trial of 1,505 patients with anterior-circulation ischemic stroke who could not receive thrombolysis, 14 days of Danhong injection increased the share with no or minimal disability at 90 days from 59% to 65%. Serious adverse events did not differ significantly; the findings apply to this selected population, and proposed blood-marker mechanisms came from only 39 patients and need independent validation.

Journal
MedComm (Q1)
Published
8 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jun Liu, Yilong Wang, Bingwei Chen, Jingjing Lu, Lin Chen, Shuang Guan, et al.
PMID
43001080
DOI
10.1002/mco2.71135

Why clinicians should know about it

  • Picked for Neurology (clinical) (top studies of the week, 15 November 2026): Randomized phase IV trial of functional recovery after acute ischemic

Abstract

Therapeutic options for neurological recovery remain limited in acute ischemic stroke (AIS) patients ineligible for thrombolysis, and while multitarget drugs like Danhong injection (DHI) demonstrate efficacy, their polypharmacological mechanisms remain understood. In this trial including 1505 thrombolysis-ineligible AIS patients with anterior-circulation and blood stasis syndrome (NCT01677208), 14-day treatment with DHI (n = 1002) versus placebo (n = 503) demonstrated superior 90-day outcomes (modified Rankin scale [mRS] score ≤1: 64.57 vs. 59.24%; adjusted odds ratio 1.43, 95%CI 1.10-1.86, p = 0.007), particularly in females and hypertensive patients, and no significant between-group differences in any serious adverse events (all p > 0.05). In the exploratory RNA-sequencing substudy of 39 patients (24 DHI, 15 placebo), we identified 19 differentially expressed modules, including two paired targeted modules "HBG2" and "TMEM108," whose topological features showed opposite correlations with the primary clinical outcome (δmRS at Day 90). Furthermore, a combination effect model was introduced to describe the time-dependent joint association of these modules with outcome (combination effect score: -0.729 at Day 0, 0.227 at Day 14, and 1 at Day 90). These findings demonstrate DHI may be a favorable treatment option for thrombolysis-ineligible AIS patients and provide a proposed analytical framework for future, independently validated studies of multitarget drug actions in complex diseases.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.